8-K filing — Skye Bioscience, Inc. (SKYE)
Filed: 2026-11-12 AccNo: 0001628280-26-073120 Size: 148 KB Item 8.01: Other Events
Stocks · News reference
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-12 AccNo: 0001628280-26-073120 Size: 148 KB Item 8.01: Other Events
Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001516551/000162828026061558/skye-20260908.htm
Skye Bioscience shares rise 6% after hours on a $22M equity purchase agreement and warrant issuance.
Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the "Company"), with the U.S. Securities and Exchange